Larimar Therapeutics (LRMR) Total Liabilities (2013 - 2025)

Larimar Therapeutics' Total Liabilities history runs 13 years deep, the most recent figure standing at $67.8 million for Q4 2025.

• Quarterly Total Liabilities rose 138.47% year-over-year to $67.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $67.8 million (up 138.47% YoY) and the FY2025 annual result came in at $67.8 million, up 138.47% from the prior year.
• Total Liabilities was $67.8 million for Q4 2025 at Larimar Therapeutics, up from $48.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $67.8 million in Q4 2025 and bottomed at $11.2 million in Q3 2023.
• A 5-year average of $21.4 million and a median of $14.9 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2021 — Total Liabilities plunged 38.0% — and 2025, when it soared 138.47%.
• Larimar Therapeutics' Total Liabilities stood at $14.3 million in 2021, then gained by 8.76% to $15.5 million in 2022, then decreased by 8.3% to $14.2 million in 2023, then jumped by 99.88% to $28.4 million in 2024, then soared by 138.47% to $67.8 million in 2025.
• Business Quant data shows LRMR's Total Liabilities at $67.8 million in Q4 2025, $48.3 million in Q3 2025, and $30.1 million in Q2 2025.